Future vaccine development at NICHD.
Using published data and the results of our studies, we hypothesized that a critical level of serum IgG antibodies to the surface structures of invasive pathogens (capsular polysaccharides of Haemophilus influenzae type b, pneumococcus, meningococcus, Salmonella typhi, Escherichia coli, and Staphylococcus aureus, the O-specific polysaccharide LPS domain of the LPS of Shigella, non-typhoidal Salmonella, and E. coli, and the capsular polypeptide of Bacillus anthraces) confer immunity to these pathogens. Covalent attachment to a protein increases their immunogenicity and bestows T-cell properties to these antigens. We have also shown that a critical level of serum IgG antibodies to pertussis toxin alone induces immunity on both an individual and on a community basis (herd immunity) to Bordetella pertussis. It is likely that all the above conjugates and pertussis toxoid will be incorporated into vaccines for routine infant immunization.
Robbins
John B
JB
Laboratory of Developmental and Molecular Immunity, NICHD, NIH, Building 6, Room 436, Bethesda, MD 20892, USA. robbinsj@nichd.nih.gov
Schneerson
Rachel
R
D001424:Bacterial Infections / Q000276:immunology / Q000517:prevention & control*; D001428:Bacterial Vaccines / Q000627:therapeutic use; D002648:Child; D002669:Child Welfare; D002675:Child, Preschool; D006801:Humans; D007114:Immunization; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D009316:National Institutes of Health (U.S.); D011135:Polysaccharides, Bacterial / Q000276:immunology; D014481:United States
D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D011135:Polysaccharides, Bacterial